Novartis’ Exforge could get lift from Norvasc patent decision

Share this article:
Yesterday’s Federal Court decision invalidating Pfizer’s Norvasc (amlodipine besylate) could give an early boost to Novartis’ Exforge. “Besides the generic companies that will be launching their cheaper formulations of Norvasc, the other company that stands to benefit is Novartis,” Prudential analyst Tim Anderson wrote in a research note issued shortly after the decision. Novartis has been holding off on launching Exforge, which combines Novartis’ Diovan (valsartan) with Norvasc in one pill, until September 2007, pending the expiration of market exclusivity and patent protection for Norvasc. Exforge won FDA approval in December. “The presumed Sept. ’07 launch could now be brought forward to March/April ’07, which is a slight positive for Novartis,” Anderson said. The Court of Appeals for the Federal Circuit Thursday reversed a lower court’s ruling in favor of Pfizer in the company’s bid to prevent Canadian generics firm Apotex from launching a copycat version of Norvasc. Mylan Laboratories, which was the first Norvasc Abbreviated New Drug Application filer, holds 180-day exclusivity rights for a generic version of the drug and could launch their version as early as next week. Pfizer said in a statement that it disagreed with the yesterday’s ruling and is considering all its options, including “seeking reconsideration” of the decision. Both Norvasc and Diovan are top-selling therapies in their respective categories. Norvasc, a calcium channel blocker, had US sales of $2.6 billion in 2005, while Diovan, an angiotensin II antagonist, racked up 2005 sales of $1.04 billion, according to IMS Health.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...